World's Best Scientists 2026 revealed!
Isamu Okamoto

Isamu Okamoto

D-Index & Metrics

Medicine

D-Index
93
Citations
41220
World Ranking
10722
National Ranking
305

Isamu Okamoto publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Isamu Okamoto sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 613 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Isamu Okamoto D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Isamu Okamoto sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Isamu Okamoto is affiliated with Kyushu University in Japan. Their research primarily centers on Medicine, with a focus on subfields including Pulmonary and Respiratory Medicine, Oncology, Epidemiology, Molecular Biology, and Immunology.

Their research topics encompass several aspects of cancer and respiratory conditions. These include:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Neuroendocrine Tumor Research Advances

Okamoto has contributed extensively to academic journals. Their frequent publication venues are:

  • Annals of Oncology (18 publications)
  • Journal of Thoracic Oncology (14 publications)
  • Lung Cancer (13 publications)
  • Journal of Clinical Oncology (11 publications)
  • Clinical Lung Cancer (7 publications)

Selected recent papers include:

  • Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial (2020), The Lancet Oncology
  • A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 (2020), Journal of Thoracic Oncology
  • Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study (2021), Journal of Thoracic Oncology
  • Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial (2023), Nature Communications
  • Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study (2021), Journal of Thoracic Oncology

Okamoto frequently collaborates with a set of coauthors, including:

  • Nobuyuki Yamamoto (32 collaborations)
  • Kentaro Tanaka (32 collaborations)
  • Shunichi Sugawara (32 collaborations)
  • Kazuhiko Nakagawa (25 collaborations)
  • Yoichi Nakanishi (22 collaborations)

Best Publications

  • Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana

  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

    Tetsuya Mitsudomi;Satoshi Morita;Yasushi Yatabe;Shunichi Negoro

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

    Mark A. Socinski;Igor Bondarenko;Nina A. Karaseva;Anatoly M. Makhson

  • Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

    Takashi Seto;Terufumi Kato;Makoto Nishio;Koichi Goto

  • Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

    K. Azuma;K. Ota;A. Kawahara;S. Hattori

  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

    Kimio Yonesaka;Kreshnik Zejnullahu;Isamu Okamoto;Taroh Satoh

  • CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Thanyanan Reungwetwattana;Kazuhiko Nakagawa;Byoung Chul Cho;Manuel Cobo

  • Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

    Shuichi Hironaka;Shinya Ueda;Hirofumi Yasui;Tomohiro Nishina

  • Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

    Keiichi Ota;Koichi Azuma;Akihiko Kawahara;Satoshi Hattori

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

    Jonathan W Goldman;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

    Luis Paz-Ares;David Vicente;Ali Tafreshi;Andrew Robinson

  • Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway

    Isamu Okamoto;Isamu Okamoto;Yoshiaki Kawano;Daizo Murakami;Takashi Sasayama

  • Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

    Masahiko Ando;Isamu Okamoto;Nobuyuki Yamamoto;Koji Takeda

  • CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration.

    Isamu Okamoto;Yoshiaki Kawano;Hiromasa Tsuiki;Ji Ichiro Sasaki

  • Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

    K Tamura;I Okamoto;T Kashii;S Negoro

  • Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

    Satoshi Morita;Isamu Okamoto;Kunihiko Kobayashi;Koichi Yamazaki

  • Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

    Taroh Satoh;Isamu Okamoto;Masaki Miyazaki;Ryotaroh Morinaga

  • Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203)

    Koji Takeda;Toyoaki Hida;Tosiya Sato;Masahiko Ando

Frequent Co-Authors

Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Kazuto Nishio
Kazuto Nishio Kindai University
Masahiro Fukuoka
Masahiro Fukuoka Kindai University
Satoshi Morita
Satoshi Morita Kyoto University
Tetsuya Mitsudomi
Tetsuya Mitsudomi Kindai University
Yoshinao Oda
Yoshinao Oda Kyushu University
Yuichiro Ohe
Yuichiro Ohe National Cancer Centre
Pasi A. Jänne
Pasi A. Jänne Harvard University
Hiroaki Okamoto
Hiroaki Okamoto Jichi Medical University
Hideyuki Saya
Hideyuki Saya Fujita Health University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and complementary healthcare career options is becoming more common for students interested in medicine in the USA. Not everyone follows the traditional medical school route—there are excellent online programs that open doors to rewarding roles in healthcare.

For example, a popular entry point is medical billing and coding. If you’re concerned about affordability, you may be wondering, can you get financial aid for medical billing and coding? Many accredited schools offer financial support for these in-demand programs.

Nursing continues to be a flexible path, with many nursing schools that don't require teas, making the admissions process less stressful for prospective nurses.

Leadership opportunities in health systems are also growing. If management interests you, consider an online healthcare management degree to advance in administrative or executive roles.

And for registered nurses aiming to become nurse practitioners, adn to np bridge programs provide a fast-track to advanced practice and specialization.

These pathways offer accessible alternatives for students eager to build a career in healthcare—fully online and with ample support.

Best Scientists Citing Isamu Okamoto

Trending Scientists